Benign Prostatic Hyperplasia: The Enlarged Prostate Conundrum

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that affects approximately 50% of men over the age of 50, with prevalence increasing to 90% by age 85. According to a study published in the Journal of Urology, the condition is characterized by lower urinary tract symptoms (LUTS), including frequent urination, weak urine flow, and nocturia. The exact cause of BPH remains unclear, but research suggests that hormonal changes, genetics, and lifestyle factors may play a role. Treatment options range from medication and minimally invasive procedures to surgery, with a 2019 study in the New England Journal of Medicine reporting that transurethral resection of the prostate (TURP) is a highly effective surgical treatment for BPH. Despite its prevalence, BPH remains a topic of debate among healthcare professionals, with some arguing that the condition is overdiagnosed and overtreated. As the global population ages, the impact of BPH on healthcare systems and individual quality of life will only continue to grow, with estimated costs exceeding $1.5 billion annually in the United States alone.